Download presentation
Presentation is loading. Please wait.
Published byPhilomena Stafford Modified over 6 years ago
1
Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA, FAHA, FCCP, FACC Journal of Clinical Lipidology Volume 7, Issue 3, Pages S6-S10 (May 2013) DOI: /j.jacl Copyright © 2013 National Lipid Association Terms and Conditions
2
Figure 1 Mechanism of action of an antisense oligonucleotide. DNA, deoxyribonucleic acid; mRNA, messenger ribonucleic acid. © Copyright Antisense Therapeutics Limited, Accessed at and reprinted with permission from Antisense Therapeutics Limited. Journal of Clinical Lipidology 2013 7, S6-S10DOI: ( /j.jacl ) Copyright © 2013 National Lipid Association Terms and Conditions
3
Figure 2 Change in LDL-C over time with 26 weeks of mipomersen treatment in a phase 3 trial in patients with homozygous FH. Reprinted with permission from Raal et al.11 LDL, low-density lipoprotein. Journal of Clinical Lipidology 2013 7, S6-S10DOI: ( /j.jacl ) Copyright © 2013 National Lipid Association Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.